<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809796</url>
  </required_header>
  <id_info>
    <org_study_id>OP-103</org_study_id>
    <nct_id>NCT00809796</nct_id>
  </id_info>
  <brief_title>A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment</brief_title>
  <official_title>A Phase I/II Clinical Study Using Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Folinic Acid, 5-Fluorouracil, or Capecitabine and Oxaliplatin Chemotherapy as Second-line and/or Third-line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncozyme Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncozyme Pharma Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and possible efficacy of the use of&#xD;
      pentamidine in the treatment of colon cancer metastasis in subjects receiving standard&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any severe events, tumor marker CEA, and tumor size (CT scan)</measure>
    <time_frame>Three Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of pentamidine in second and/or third line metastatic colon cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentamidine</intervention_name>
    <description>one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven diagnosis of adenocarcinoma of the colon or&#xD;
             rectum with evidence of (1) unresectable, locally recurrent, or (2) metastatic disease&#xD;
&#xD;
          -  Failure of first-line or second-line therapy for colorectal cancer&#xD;
&#xD;
          -  At least one unidimensional measurable lesion (on spiral CT scan)&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  ECOG performance status 0, 1 or 2&#xD;
&#xD;
          -  Serum aspartate transaminase (AST) serum alanine transaminase (ALT) £ 2.5 x upper&#xD;
             limit of normal (ULN), or AST and ALT £ 5 x ULN if liver function abnormalities are&#xD;
             due to underlying malignancy&#xD;
&#xD;
          -  Total serum bilirubin £ 1.5 x ULN&#xD;
&#xD;
          -  Serum albumin ≥ 3.0 g/dL&#xD;
&#xD;
          -  lipase within normal limits&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1500/uL (1.5 x 109/L)&#xD;
&#xD;
          -  Platelets ≥ 100,000/uL&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Serum creatinine £ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml/min&#xD;
&#xD;
          -  Magnesium ≥ lower limit of normal&#xD;
&#xD;
          -  CEA level ≥ 3.4 ng/ml&#xD;
&#xD;
          -  Normal ECG&#xD;
&#xD;
          -  Signed and dated informed consent document indicating that the subject (or legally&#xD;
             acceptable representative) has been informed of all the pertinent aspects of the trial&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other trial procedures&#xD;
&#xD;
          -  Life expectancy, in the opinion of the investigator, &gt; 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BP &lt; 100 (systolic)&#xD;
&#xD;
          -  History of renal disease, pancreatitis, or diabetes mellitus&#xD;
&#xD;
          -  Peripheral sensory neuropathy (&gt; Grade 1, as per NCI CTCAE version 3.0)&#xD;
&#xD;
          -  Concomitant therapy with other investigational agents or participation in another&#xD;
             clinical trial&#xD;
&#xD;
          -  Any of the following conditions: Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2;&#xD;
             atrial fibrillation of any grade; QTc interval &gt;450 msec for males or &gt;470 msec for&#xD;
             females or uncontrolled intercurrent illness, e.g., unstable angina; severe coronary&#xD;
             disease, ventricular arrhythmias, bradycardia &lt;50 bpm&#xD;
&#xD;
          -  Active uncontrolled bacterial infection&#xD;
&#xD;
          -  Concurrent use of drugs that could prolong QT interval&#xD;
&#xD;
          -  Concurrent use of nephrotoxic drugs, including aminoglycosides, ampho B, foscarnet,&#xD;
             cidofovir&#xD;
&#xD;
          -  Concurrent use of drugs that may be associated with pancreatitis&#xD;
&#xD;
          -  Concurrent active cancer originating from a primary site other than colon/rectum,&#xD;
             except for surgically treated nonmelanoma skin cancer, in situ cervical cancer, or&#xD;
             localized prostate cancer with undetectable PSA level&#xD;
&#xD;
          -  Co-existing lung disease&#xD;
&#xD;
          -  History of allergy or hypersensitivity to pentamidine Pregnancy or breastfeeding. All&#xD;
             female patients with reproductive potential must have a negative pregnancy test (serum&#xD;
             or urine) prior to first dose of study medication.&#xD;
&#xD;
          -  Severe acute or chronic medical or psychiatric condition, or laboratory abnormality&#xD;
             that would impart, in the judgement of the investigator, excess risk associated with&#xD;
             trial participation of study drug administration, or which in the judgement of the&#xD;
             investigator, would make the subject inappropriate for entry into this trial.&#xD;
&#xD;
          -  On oral anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Kavan, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital/McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>June 27, 2011</last_update_submitted>
  <last_update_submitted_qc>June 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Terry Chow/President</name_title>
    <organization>Oncozyme Pharma Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

